Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus
Authors' conclusion
This analysis shows that non-adherence to cardiometabolic drug regimens is common in type 2 diabetes mellitus and negatively affects kidney and cardiovascular outcomes.
Study context
- Population
- Patients with T2D followed at the primary care level in the PROVALID study; baseline urine tested for 79 cardiometabolic drugs and metabolitesPROVALID study
- Participants
- 1,125 patients
- Exposure
- Non-adherence vs adherence to cardiometabolic drugs
- Outcome
- Non-adherence to screened cardiometabolic drugs
- Follow-up
- Baseline
Methodological detailsprimary care level, direct adherence measure by LC-MS/MS in urine
- Primary care level
- Direct adherence measure by LC-MS/MS in urine
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Cardiovascular outcome (composite of MI, stroke and cardiovascular death) with non-adherence to antiplatelet drugs · median (IQR) follow-up 5.10 (4.12-6.12) years
| HR (95% CI) | ||
|---|---|---|
| Non-adherence to antiplatelet drugsWorse cardiovascular outcomes | 10.13 (3.06–33.56) | |
| 0.050.21520Hazard ratio (log scale) |
Kidney outcome (composite of sustained 40% decline in eGFR, sustained progression of albuminuria, kidney replacement therapy and death from kidney failure) with non-adherence to antihypertensive drugs · median (IQR) follow-up 5.10 (4.12-6.12) years
| HR (95% CI) | ||
|---|---|---|
| Non-adherence to antihypertensive drugsWorse kidney outcomes | 1.98 (1.37–2.86) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →